Skip to main content

Research

The latest research in type 1 diabetes, type 2 diabetes, prediabetes, and beyond. Here you’ll find information on experimental therapies, new data and results, and scientific findings.

Ozempic, a once weekly injectable GLP-1 agonist drug, is now approved to reduce the risk of heart attack and stroke. Rybelsus (a pill version of Ozempic) is confirmed to...
A new study shows that physical activity can add years to your life. Is this enough to motivate behavior change?
Check out the third day highlights from ADA’s virtual 80th Scientific Sessions – including new insights on off label use in type 1 diabetes, type 2 diabetes remission,...
In exciting news, Tandem announced expanded clearance for the hybrid closed loop Control-IQ. The system is now available for children ages 6-13
The first study of people with diabetes and COVID-19 reveals troubling statistics and risk factors
Results from the VERTIS-CV trial show that SGLT-2 inhibitor Steglatro benefits heart and kidney health; hear expert opinions on SGLT-2 and GLP-1 medications
dQ&A surveyed 2,540 CGM users with type 1 or type 2 diabetes to find out how aware they are of their own time in range: 87% of respondents knew how much time they...
What is the link between vision loss and mental health outcomes, and how can eye exams tell us what is going on in the brain and the body?
Trulicity can now be prescribed to reduce the risk of stroke and heart attack in adults with type 2 diabetes and with heart disease or those who at risk for heart disease
JDRF's Mission Summit in La Jolla, California highlighted JDRF's efforts into multiple cures, plus more on complications
In exciting news for digital diabetes prevention programs, a new study showed that highly engaged participants – those who more frequently engaged in food logging,...
We bring you the most exciting news from day one, including updates on automated insulin delivery, ways that technology can reduce hypoglycemia, and new physical...
Highlights from last week’s European Association for the Study of Diabetes’ (EASD) virtual 2020 conference included announcements on the Guardian Sensor 4 Continuous...
Recent results from Omada Health’s Digital Diabetes Prevention Program show reductions in A1C and body weight over a 12-month period. This digital tool may be especially...
The RADIANT study aims to define unusual forms of diabetes, to help diagnose and treat these conditions. RADIANT is recruiting people who have been diagnosed with...
At the ADA Postgraduate 2021 virtual conference, Dr. Samuel Dagogo-Jack discussed how intensive lifestyle changes can lead to prediabetes remission and prevent...
Latest results presented at the European Society of Cardiology conference show that SGLT-2 inhibitor therapies Jardiance and Farxiga clearly lead to heart and kidney...
Experts discussed the greatest challenges in diabetes in 2020, including the COVID-19 pandemic, and the most critical changes we need to make to address them during...
Diabetes increases the risk of severe COVID-19 illness, but does the relationship between diabetes and the virus go in the other direction? Scientists are now studying...
Emerging evidence shows that variability in your A1C level may put you at a higher risk of stroke and heart disease.

Pages